GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (FRA:FP1) » Definitions » Equity-to-Asset

Salarius Pharmaceuticals (FRA:FP1) Equity-to-Asset : 0.75 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Salarius Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €3.36 Mil. Salarius Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €4.49 Mil.

The historical rank and industry rank for Salarius Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

FRA:FP1' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18   Med: 0.89   Max: 0.98
Current: 0.75

During the past 10 years, the highest Equity to Asset Ratio of Salarius Pharmaceuticals was 0.98. The lowest was -0.18. And the median was 0.89.

FRA:FP1's Equity-to-Asset is ranked better than
59.4% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:FP1: 0.75

Salarius Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Salarius Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Equity-to-Asset Chart

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.89 0.95 0.71 0.80

Salarius Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.70 0.72 0.80 0.75

Competitive Comparison of Salarius Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Salarius Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Equity-to-Asset falls into.



Salarius Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Salarius Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.848/6.04
=

Salarius Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=3.358/4.493
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Salarius Pharmaceuticals  (FRA:FP1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Salarius Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (FRA:FP1) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Salarius Pharmaceuticals (FRA:FP1) Headlines

No Headlines